CD37-positive AML cells were sensitive to IMGN529, an antibody-drug conjugate (ADC) targeting CD37, and the viability of AML cells declined in response to an increased concentration of IMGN529 (Larkin et al., 2018). The gene discussed is CD37; the disease is acute myeloid leukemia.